The present study investigates the receptor and mechanisms involved in @entity855 -stimulated @entity1810 ( @entity1810 ) mRNA expression of a type-2 astrocyte cell line, RBA-2. RT-PCR analysis revealed that RBA-2 type-2 astrocytes possess abundant @entity22753 and @entity23621 (7) receptors. @entity855 and @entity23621 (7) receptor-sensitive agonist, @entity22657 , both stimulated @entity1810 mRNA expression in a time and dose-dependent manner. The stimulation required a minimum of 500 muM @entity855 ; @entity22657 was much more potent that @entity855 , and @entity23621 (7)-selective antagonist, @entity64554 , inhibited the effects. In addition, @entity855 metabolites @entity857 , @entity860 and @entity859 were ineffective in stimulation of @entity1810 mRNA expression. Thus, the effect of @entity855 was mediated through the P2X(7) receptors. To investigate further the mechanisms by which the P2X(7) receptor mediated the @entity1810 mRNA expression, the cells were treated with inhibitors for mitogen-activated kinase (MAPK) or @entity7131 ( @entity7131 ), @entity4286 or @entity11009 , respectively. Both @entity4286 and @entity11009 inhibited the @entity855 -stimulated @entity1810 mRNA expression. Furthermore, @entity855 and @entity22657 stimulated @entity2508 activation and the activation was inhibited by @entity7131 inhibitors, @entity11009 and G  6976. In conclusion, activation of P2X(7) receptors enhanced @entity1810 mRNA expression and the effect involved @entity7131 /MAPK signalling pathway in RBA-2 type-2 astrocytes.

Activation of P2X7 purinoceptor-stimulated XXXX mRNA expression involves @entity7131 /MAPK signalling pathway in a rat brain-derived type-2 astrocyte cell line, RBA-2.

@entity859 :: ('MESH:D000241', 'Chemical') :: ['adenosine'] @entity23621 :: ('p|SUB|P|2|X', 'ProteinMutation') :: ['P2X'] @entity22753 :: ('29659(Tax:10116)', 'Gene') :: ['P2X(4)'] @entity64554 :: ('MESH:C004282', 'Chemical') :: ['oATP'] @entity857 :: ('MESH:D000244', 'Chemical') :: ['ADP'] @entity2508 :: ('50689;116590', 'Gene') :: ['ERK1/2'] @entity7131 :: ('MESH:D020151', 'Disease') :: ['protein kinase C', 'PKC'] @entity11009 :: ('MESH:C070515', 'Chemical') :: ['GF109203X'] @entity1810 :: ('59086(Tax:10116)', 'Gene') :: ['TGF-beta 1', 'transforming growth factor-beta 1'] @entity4286 :: ('MESH:C093973', 'Chemical') :: ['PD98059'] @entity860 :: ('MESH:D000249', 'Chemical') :: ['AMP'] @entity22657 :: ('MESH:C033901', 'Chemical') :: ['BzATP'] @entity855 :: ('MESH:D000255', 'Chemical') :: ['ATP']
@entity1810 :: (59086(Tax:10116),Gene) :: ['TGF-beta 1']
